{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-177426","form_type":"8-K","ticker":"ACH","cik":"0000075252","company_name":"ACCENDRA HEALTH INC/VA/","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.285816+00:00","generated_at":"2026-05-17T15:54:18.648483+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Owens & Minor Q2: GAAP loss from continuing ops $83.8M; Products & Healthcare segment classified as discontinued ops","bullets":["Revenue from continuing ops $681.9M, up 3% YoY from $660.4M.","GAAP loss from continuing ops $(83.8)M vs $(6.7)M in 2Q24; adjusted net income $20.5M vs $19.3M.","Adjusted EBITDA from continuing ops $96.6M, up 6% from $91.1M.","Company in final stages of divestiture of Products & Healthcare Services segment; classified as discontinued ops.","2025 continuing ops financial outlook to be provided during 8:30 a.m. EDT earnings call."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-177426","json":"https://secwatch.observer/filing/0001193125-25-177426.json","markdown":"https://secwatch.observer/filing/0001193125-25-177426.md","text":"https://secwatch.observer/filing/0001193125-25-177426.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/75252/000119312525177426/0001193125-25-177426-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/75252/000119312525177426/d47157d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:54:18.648483+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}